Phase I Randomized, Placebo-Controlled, Cross-Over, Dose-Finding Pharmacokinetic Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 May 2018
At a glance
- Drugs Ubidecarenone (Primary) ; Doxorubicin
- Indications Early breast cancer
- Focus Adverse reactions
- 30 Jun 2015 Planned End Date changed from 1 Sep 2013 to 1 Sep 2016 ClinicalTrials.gov record
- 30 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 14 Jul 2010 Planned end date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.